Abstract We identified two afibrinogenemic girls in two Japanese families and performed molecular analysis to clarify the mechanisms of fibrinogen defects. Genetic analyses were performed by PCR amplification of the fibrinogen gene and DNA sequence analysis. To analyze the mechanisms of mature fibrinogen defects in plasma, we cloned minigenes from the proposita's PCR-amplified DNA, transfected them into CHO cells, and sequenced the cDNA amplified with the RT reaction followed by PCR. Sequence analyses indicated that one was caused by a homozygous 1238 bp deletion of the fibrinogen Aa-chain gene (FGAD1238) and the other was a compound heterozygous FGAD1238 and novel FGA c.54?3A[C substitution. The minigene corresponding to FGAD1238 generates two aberrant mRNAs, both of which may induce a frameshift and terminate prematurely. In contrast, the minigene corresponding to FGA c.54?3A[C generates two aberrant mRNAs, one of which may induce a frameshift and terminate prematurely, and the other uses a cryptic 5 0 splice site in exon 1, resulting in the deletion of six amino acids in signal peptides. Molecular analyses of both genetic variants suggest that the lack of a mature Aachain, impaired assembly, and/or secretion of the fibrinogen molecule may lead to afibrinogenemia.
Introduction
Fibrinogen is a 340 kDa plasma glycoprotein composed of two sets of three different polypeptide chains (Aa, Bb, and c), and it is expressed as (Aa, Bb, c) 2 . Each chain is synthesized, assembled into a six-chain molecule in hepatocytes, secreted into the blood, and circulated at 1.8-3.5 g/l [1, 2] . Aa-, Bb-and c-chains in plasma fibrinogen are composed of 610, 461 and 411 amino acid residues, which are composed of 3 genes coding for fibrinogen beta (FGB), fibrinogen alpha (FGA), and fibrinogen gamma (FGG), clustered in a region of approximately 50 kb on chromosome 4q31.3 [3] . Genetic mutations in fibrinogen chain genes have been associated with afibrinogenemia, hypofibrinogenemia and dysfibrinogenemia, as listed in the fibrinogen variant database [updated on 26/01/2012, http://site.geht.org/site/Pratiques-Professionnelles/Basede-donnees-Fibrinogene/Base-de-donnees/Base-de-donneesdes-variants-du-Fibrinogene_40_.html].
Afibrinogenemia is a life-long bleeding disorder associated with the complete deficiency of plasma fibrinogen; however, the prevalence of afibrinogenemia is lower than 1 in 1 million. The severity of the bleeding tendency varies in afibrinogenemic patients. The most typical symptom is umbilical cord bleeding and other relatively frequent symptoms are hemorrhage from the mucosal tracts, hemarthroses, and hematomas, although life-threatening bleeding such as splenic rupture, gastrointestinal hemorrhage and central nervous system bleeding may be rare [4, 5] .
Genetic abnormalities and the molecular bases in patients with afibrinogenemia have been found in all three genes and identified as missense, nonsense, or frameshift mutations; splice-site abnormalities; or large deletions [4] [5] [6] [7] [8] . In particular, reports causing large deletions between 1.2 and 15 kb were restricted in FGA (fibrinogen variant database). Recently, we identified two afibrinogenemias, caused by homozygous deletion of 1238 bases of the Aachain gene (FGAD1238) and compound heterozygous deletion of FGAD1238 and FGA c.54?3A[C, examined the molecular basis of the lack of protein, and designated them as Fibrinogen Yokkaichi and Fibrinogen Kurashiki II, respectively.
Materials and methods

Patients and sampling of plasma and DNA
The Yokkaichi proposita was a 4-month-old girl who was found to have persistent omphalorrhagia 6 days after birth and progressed to intradural hematoma and hemorrhagic shock. Her fibrinogen level was less than the detection limit and she was diagnosed with afibrinogenemia and was drip infused with fibrinogen concentrates once every 3 days until the intradural hematoma disappeared. Now, fibrinogen concentrate is used only when she has a bleeding event. The parents had no obvious consanguinity and none of her family had a bleeding tendency or thrombotic complications.
The Kurashiki II proposita was a 1-year-old girl, who was hospitalized with infectious enterogastritis, and a hematoma developed at the antibiotic drip infusion site; her blood coagulation screening test indicated impaired clot formation. She was drip infused with fibrinogen concentrates during hospitalization. The parents had no consanguinity and none of her family had a bleeding tendency or thrombotic complications.
Blood was collected from both propositae and parents with informed consent for coagulation and genetic analyses. Nine volumes of blood were collected into plastic tubes containing 1 volume of 3.2 % trisodium citrate. Separated plasma was used for coagulation tests and buffy coat cells were extracted to prepare genomic DNA [9] . This analysis was approved by the Ethics Committee for Genetic Analysis of Shinshu University School of Medicine.
Coagulation screening tests
Blood coagulation screening tests; prothrombin time (PT), activated partial thromboplastin time (APTT), the fibrinogen concentration, which was determined by the thrombin time method, and the immunologic fibrinogen concentration were measured as described elsewhere [9] .
DNA sequence analysis and long-range polymerase chain reaction (PCR)
To analyze all exons and exon-intron boundaries in the Aa-, Bb-, and c-chain genes, PCR and direct sequencing were performed as described elsewhere [9] . To examine the large deletion of the genes, long-range PCR for the entire Aa-, Bb-, and c-chain genes was performed using the TaKaRa LA Taq (Takara Bio Inc., Otsu, Japan) and the pair of primers for Aa-chain: sense primer: . Amplification was performed with 1 lg genomic DNA and PCR conditions were as follows: an initial denaturation step at 94°C for 1 min, 30 cycles of denaturation at 98°C for 10 s and annealing at 66°C for 15 min, and final extension at 72°C for 10 min. PCR products were electrophoresed on a 1.0 % agarose gel and stained with ethidium bromide.
Construction of expression vectors
To amplify the DNA fragments spanning from intron 2 to exon 5 including FGAD1238 and from 5 0 untranslated region (UTR) to intron 2 including intron 1 point mutation of the Aa-chain gene (FGA c.54?3A[C), PCR was performed using the Kurashiki II patient's genomic DNA and the primers: sense primer located in FGA-IVS2 (5 0 -GAA AGGGTAGGAAGAAATGGGG-3 0 ) and antisense primer located in FGA-exon 5 (5 0 -CCTGGGGCTTTCCGTCTCT GA-3 0 ), or sense primer located in FGA-UTR (5 0 -CAGCT AGCTTACCTAAGCACC-3 0 ) and antisense primer located in FGA-IVS2 (5 0 -CACCCACTAATGATCCAGAGTT GG-3 0 ). Purified DNA fragments including FGAD1238 (Mt1: 1258 bp), FGA c.54 ? 3A (Wt2: 1826 bp), and FGA c.54 ? 3C (Mt2: 1826 bp) were inserted into pTARGET Vector (Promega, Co., Madison, WI, USA) and transfected into JM109 High Efficiency Competent Cells (Promega) according to the manufacturer's instructions. Plasmid containing wild-or mutant-type DNA fragment (named as pT-Aa-Mt1, pT-Aa-Wt2, or pT-Aa-Mt2 vector, respectively) was purified using a Qiagen Plasmid Maxi Kit (Qiagen GmbH, Hilden, Germany) and the nucleotide sequences were confirmed.
Analyses for mRNAs transcripted from FGAD1238 and FGA c.54 ? 3C DNA fragments Eight micrograms of each expression vector was introduced into approximately 0.5-1 9 10 6 of Chinese hamster ovary (CHO) cells in a 6-cm culture dish using lipofectamine reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's protocol. The transfected CHO cells were cultured in 5 % CO 2 at 37°C.
The CHO cells were harvested 48 h after transfection. Total cellular RNA was extracted from cells using the QIAamp RNA Blood Mini Kit (Qiagen), and contaminated DNA was digested using the QIA shredder column and DNase, according to the manufacturer's instructions. Reverse-transcriptase (RT) reactions were carried out using oligo dT primer and RT from Moloney murine leukemia virus, followed by PCR amplification with the two pairs of primers that were used in the construction of expression vectors under the following conditions: 30 cycles of denaturation at 94°C for 1 min, annealing at 56°C (FGAD1238) or 57°C (FGA c.54?3A[C) for 1 min, and extension at 72°C for 1 min.
The RT-PCR amplified products (cDNA) were separated by electrophoresis on 2.0 % agarose gels and purified DNA fragments were sequenced using the primers used for the construction of expression vectors. Moreover, to clarify the frequency of mRNA, the RT-PCR amplified products were inserted into pCR2.1Vector (Invitrogen, San Diego CA, USA) and transfected into INVaF' Competent Cells (Invitrogen) according to the manufacturer's instructions. Plasmids containing cDNA were purified from 15 colonies and sequenced as described above.
Haplotype analysis
The following 7 polymorphic loci neighboring the fibrinogen gene cluster on chromosome 4 were used for haplotype analysis: D4S2962, D4S2934, D4S2999, D4S3021, FGA-i3 (a TCTT repeat located in intron 3 of the FGA), D4S2631, and D4S1629 (ordered from centromere to telomere, according to the NCBI Map Viewer http://www.ncbi.nlm.nih.gov/projects/ mapview/). The repeated regions of each short tandem repeat (STR) locus were amplified by PCR for 40 cycles using the two pairs of primers under the following conditions: denaturation at 96°C for 30 s, annealing at 55°C for 1 min, and extension at 72°C for 2.5 min (Table 1) . PCR products were diluted by distilled water and mixed with Hi-Di Formamide and GeneScan-350 ROX Size Standard. The samples were electrophoresed on an ABI Prism 310 Genetic Analyzer and fluorescent signals were analyzed with the aid of Gene Scan 3.1 software (both from Applied Biosystems).
Results
Coagulation screening tests
PT, APTT, and the fibrinogen concentration, which was determined by the thrombin time method, of plasma from both Yokkaichi and Kurashiki II propositae showed a markedly prolonged clotting time or a lower concentration than the detection limit, respectively, whereas those of plasma from the parents of both propositae were within their reference ranges, indicating a normal level of fibrinogen (Table 2) . Plasma fibrinogen concentration determined by the immunological method was 0.15 g/l for Yokkaichi and 0.028 g/l for Kurashiki II ( Table 2) .
PCR amplification and DNA sequence analysis Amplification and sequence analysis for all exons and exon-intron boundaries in the Aa-, Bb-, and c-chain genes indicated the following results; no amplification product was obtained from exon 4 of the Aa-chain gene for the Yokkaichi proposita, heterozygous FGA c.54?3A[C (reference gene: GenBank accession # NM_000508.3) substitution was found in the Kurashiki II proposita and her mother (Table 2) , and no abnormality was found in other regions of DNA from the two propositae and parents (data not shown).
From these results, we considered the possible large deletions in Aa-, Bb-, and/or c-chain genes. To amplify each entire gene, long-range PCR amplification was performed as described in ''Materials and methods''. Although Bb-and c-chain genes showed wild-type base sizes (7735 and 8934 bp, respectively) for all 6 persons, the Aa-chain gene indicated aberrant small DNA (4380 bp which is 1238 bp smaller than the size of wild type, 5618 bp) in the Yokkaichi proposita and her parents, and also in the Kurashiki II proposita and her father. The Yokkaichi proposita had only aberrant small DNA and the others had both aberrant and wild-type DNA (Fig. 1) . The nucleotide sequence of aberrant small DNA of the Aa-chain gene was determined by direct sequence analysis. The sequence showed a large deletion of FGA (c.364 ? 86_510 ? 43del1238) (reference coding DNA: GenBank accession # NM_ 000508.3) for the Yokkaichi proposita, her parents, the Kurashiki II proposita, and her father ( Table 2) . Genomic DNA was deposited as GenBank accession # M64982.1 [10] .
Analysis of fibrinogen Aa-chain gene transcripts in CHO cells
To verify whether the DNA mutation of FGAD1238 and FGA c.54 ? 3C influences the transcription of mature mRNAs, mutant Aa-chain mRNAs were transiently produced in CHO cells and analyzed as described in ''Materials and methods''. The RT-PCR products from CHO cells transfected with pT-Aa-Mt1 showed two bands, which were named Aa-M1-1 and Aa-M1-2, respectively (Fig. 2a) . Direct sequencing demonstrated that the mRNA of Aa-M1-1 was a combined product of exon 3, intron 3, intron 4, and exon 5, whereas the mRNA of Aa-M1-2 was a splicing product of exons 3 and 5 (Fig. 2a) . The frequency of the mRNA of Aa-M1-1 and Aa-M1-2 was 14 % (2/14) and 86 % (12/14), respectively.
The RT-PCR products from CHO cells transfected with pT-Aa-Wt2 showed a single band that was named as Aa-W2, and those with pT-Aa-Mt2 showed two bands, which were named Aa-M2-1 and Aa-M2-2, respectively (Fig. 2b) . Direct sequencing showed that Aa-W2 had normal mRNA with correct splicing of exons 1 and 2. The mRNA of Aa-M2-1 was a combined product of exon 1, intron 1, and exon 2, whereas the mRNA of Aa-M2-2 included two products, one (Aa-M2-2A) was a normal splicing product of exons 1 and 2, and the other (Aa-M2-2B) was an aberrant splicing product of exons 1 and 2 using a cryptic 5 0 splice site 18-nt upstream from the end of exon 1 (Fig. 2b) . The frequency of the mRNA of Aa-M2-1, Aa-M2-2A and Aa-M2-2B was 46 % (6/13), 8 % (1/13), and 46 % (6/13), respectively.
Haplotype analysis of chromosome 4q adjacent to fibrinogen gene
Haplotype analysis (D4S2999, D4S3021, FGA-i3, and D4S2631) revealed that the deletions of FGAD1238 were present on three different chromosomes, with haplotypes 217-234-del-212, 217-232-del-204, and 207-232-del-212 (Fig. 3) . On the other hand, FGA c.54 ? 3C mutation was present on the chromosome with haplotypes 215-232-199-208 (Fig. 3) .
Discussion
In this study, we described two afibrinogenemias, Fibrinogen Yokkaichi and Kurashiki II, each caused by a homozygote of FGAD1238 and a compound heterozygote of FGAD1238 and FGA c.54 ? 3C, respectively. The six families, including our two cases, with FGAD1238 mutation have only been found in Far Eastern countries, one in China [11] and five in Japan [12] (E Hamada, T Sawamura, N Yokota, M Maekawa: abstract P13-05, 54th Annual Meeting of the Japanese Society of Laboratory Medicine, Nov. 2007, in Japanese), and (T Sawamura, E Hamada, N Kanayama, M Maekawa: abstract O-171, 55th Annual Meeting of the Japanese Society of Laboratory Medicine, Nov. 2008, in Japanese). Although FGA c.54?3A[C substitution is a novel mutation, A[G substitution at an identical site (FGA c.54?3A[G) has been reported in France [13] .
To examine the causes of the low level of plasma fibrinogen in individuals with FGAD1238 mutation or FGA c.54?3A[C substitution, we analyzed the mRNAs transcribed from the cloned mutant Aa-chain genes in CHO cells. A minigene corresponding to FGAD1238, which included the region between intron 2 and exon 5, generated two mRNAs. One was a non-spliced product and the other was a spliced product connecting exons 3 and 5, both of which induced a frameshift of coding amino acids and finally terminated at premature termination codons 114 and 106, respectively. On the other hand, a minigene corresponding to FGA c.54 ? 3C, which includes nucleotides between the 5 0 -flanking region and intron 2, generated three mRNAs. One is a normal splicing product but with only 8 % Aa-chain mRNA. The others are a non-splicing product and an aberrant splicing product. The former might induce a frameshift of coding amino acids and finally terminate at premature termination codon 31. The latter uses the cryptic 5 0 splice site in exon 1, resulting in deletion of 6 amino acids (-7 to -2; VVGTAW) of signal peptides of the Aa-chain composed of 19 amino acids (-19 to -1). Overall, the above-mentioned mRNAs generating the premature termination codon might be degraded by the nonsense-mediated mRNA decay system, causing a deficiency of intact Aa protein [14, 15] , whereas the mature Aa-chain having aberrant signal peptides might lead to impaired secretion because signal peptides play a crucial role in the transportation of protein in the cell and secretion of the protein outside the cell.
In Europe and the United States of America, a 11 kb deletion of the Aa-chain gene and FGA c.510?1G[T substitution have been reported as afibrinogenemia in 8 and 14 families, respectively (fibrinogen variant database). Furthermore, haplotype analysis indicates that each mutation occurred on several different ancestral chromosomes [13, 16, 17] . In particular, the 11 kb deletion of the Aachain gene was caused by non-homologous (illegitimate) recombination [18] , whereas the 6 families with the FGAD1238 mutation were found only in Far Eastern countries, and our haplotype analysis indicated the possibility that the 3 mutation genes might be derived from three different origins, namely, nucleotide deletion events occurred on 3 different ancestral chromosomes. We also speculate that the FGAD1238 mutation might arise from non-homologous recombination similar to the 11 kb deletion of the Aa-chain gene.
Although the parents of both propositae were heterozygous for fibrinogen Aa-chain gene mutation of FGAD1238 or FGA c.54 ? 3C, their plasma fibrinogen levels were each in the normal range. This was unusual because both FGAD1238 and FGA c.54 ? 3C mutations are the non-synthesizing type of fibrinogen Aa-chain, suggesting that heterozygotes have a lower level of Fig. 1 Detection of Aa-chain gene deletion by long-range PCR amplification. Long-range PCR detected the deletion of the fibrinogen Aa-chain gene. Normal control subject showed a 5618 bp PCR product, whereas the Yokkaichi proposita, her parents, the Kurashiki II proposita, and her father showed shorter products (4380 bp). M DNA size marker, YP Yokkaichi proposita, YF Yokkaichi father, YM Yokkaichi mother, KP Kurashiki II proposita, KF Kurashiki II father, KM Kurashiki II mother, NC Normal control fibrinogen (1/2-1/4 of wild type). Afibrinogenemias caused by splicing abnormalities have been reported as homozygous mutations, and there is a report that a heterozygous splice site mutation of the Aa-chain gene does not cause hypofibrinogenemia [19] . We considered that the plasma fibrinogen level might be regulated by the expression level of Bb-and/or c-chain. Previous studies of fibrinogen synthesis with Bb-chain cDNA in HepG2 or COS-1 cells have shown that an excess amount of Aa-and c-chains accumulated in the cells [20] [21] [22] [23] , suggesting that the synthesis of the Bb-chain is a rate-limiting peptide for the assembly and secretion of mature fibrinogen. Finally, we speculated that the normal level of plasma fibrinogen in the Yokkaichi and Kurashiki II parents was caused as follows: synthesis of an excess amount of normal Aa-chain mRNA (and peptide) from the normal allele compensates for aberrant Aa-chain mRNA (and peptide) or a reduced level of Aachain mRNA (and peptide) from the mutant allele.
In conclusion, we report two cases of afibrinogenemia, Yokkaichi and Kurashiki II, caused by homozygous FGAD1238 and a compound heterozygous for FGAD1238 and FGA c.54 ? 3C, respectively. Molecular analyses of both genetic variants suggested that the lack of a mature Aa-chain, impaired assembly and/or secretion of fibrinogen molecule might lead to afibrinogenemia. 
